UNSPSC 51433914: Elgodipine

This classification denotes a calcium channel blocker with the molecular formula C29H33FN2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3JI11Z5REF, chemically known as 3,5-pyridinedicarboxylic acid, 4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-, 2-(((4-fluorophenyl)methyl)methylamino)ethyl 1-methylethyl ester, (+-)- but generally known as elgodipine, which bears US NIH Compound Identifier 60701.

UNSPSC 51433914 Elgodipine, a Commodity code, covers specific pharmaceutical active ingredients procured by state and local governments for emergency medical services, public health programs, and multi-state cooperative purchasing initiatives. State and local buyers source individual medication line items—including elgodipine and related cardiovascular agents—through sealed competitive bids, RFPs, and cooperative purchasing agreements that specify National Drug Codes, packaging configurations, expiration-date requirements, and delivery terms. Issuing bodies span city fire rescue departments, state health and human services agencies, and multi-state cooperative purchasing alliances that aggregate demand across member jurisdictions. The City of Tampa's Fire Rescue and the Texas Health and Human Services Commission represent the mix of municipal emergency services and state health agencies soliciting under this code.

Recent activity centers on Florida and Minnesota through multi-state cooperative vehicles. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem vials for Tampa Fire Rescue in Hillsborough County, with an estimated contract value of $40,000 and a one-year term plus optional renewals; the bid included a 5 percent Small Local Business Enterprise discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (due March 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities, including Oregon, through three authorized wholesalers, with a two-year initial term and performance penalties of $200 to $1,500 per violation. The Texas Health and Human Services Commission issued RFI HHS0017013 (April 3, 2026) exploring direct-to-manufacturer prescription capabilities for future state pharmacy benefit program implementation.